Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
about
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cellsAdoptive immunotherapy for cancer: building on successAdoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaCancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesDendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancerImmunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapyT-cell receptor gene therapy--ready to go viral?Prospects for exosomes in immunotherapy of cancerChemophototherapy: An Emerging Treatment Option for Solid TumorsSafety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasRelapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinityRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineCD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaAdvanced malignant melanoma: immunologic and multimodal therapeutic strategiesPTEN knockout prostate cancer as a model for experimental immunotherapyChemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity.Stromal reengineering to treat pancreas cancerBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerLow-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Photodynamic therapy and anti-tumour immunity.Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamideOptimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switchGene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceUse of tumour-responsive T cells as cancer treatment.Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Targeting CD8+ T-cell tolerance for cancer immunotherapy.Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer.Therapeutic cancer vaccines: are we there yet?Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
P2860
Q24540135-65DB73CF-EC2F-47F3-833E-F877150B6FB4Q24546258-FEA84E10-57A5-4F1D-A9FE-102A3B013573Q24548019-37EF2D5B-423D-45C4-ADFD-D33E25B1FE0CQ24676216-E74F429C-014D-4F0D-B906-34969767A863Q26822730-283DDD0E-BC82-40DA-A24B-75E797151483Q26861293-1CE6BD6A-3171-47C9-A7D3-AE61516815EAQ27027093-078B4C32-2372-4849-A5E5-DBC43EDCD0E4Q28081611-E1DB1738-3B2D-48F0-8338-C1D2121776B5Q28248098-D325A5D4-C896-4BFB-A715-6A9E1E540F84Q28468315-FA2F3711-8772-45EF-BFB4-DFB11773DFB3Q29622949-EC1E0159-8C38-42A8-BD7A-267C986B58A2Q30413827-E758F82D-1621-482B-9334-5BF9AA85E62FQ30425914-44DBA1DC-426A-4357-84C5-919B3C16D86EQ30533257-2B74D439-F37F-4763-BD88-F44F7E8854E5Q33342339-0E20A483-FC2E-4787-85A8-FFB307801185Q33717891-1FD4E226-1FBC-4C42-AA64-9200B3B835CBQ33728431-84816BBD-2531-4039-9446-B004EC048260Q33754618-312DFA95-F11F-439B-A2BC-B2C8F4EF5046Q33756565-7CB9A1E1-42CA-44CA-9318-F655E075764AQ33801059-8C325FD9-89C0-4756-A957-72925C842844Q33827708-507C68BD-190E-489F-9F09-684C1CAC9FF2Q33862861-BE595BDD-D833-426F-837C-24BBF3D88138Q33871059-8FE01C9F-530F-400E-A00D-48C3D326717AQ33942806-CBBBD207-CB48-46D3-88BF-05EAFBC0AEEDQ34041792-15D6D339-3F30-4AE1-B200-F567165DB626Q34063120-02FC4611-0188-4E37-B905-AF3E2873AB0AQ34105703-6F5BA7D2-384A-48DE-8FCA-4C98FFDB751BQ34138598-35B61AD6-741F-463A-A163-B58C518B4C93Q34146406-99FC43C4-ACF4-42E5-BC3C-0026EDAC7DDEQ34245416-827CDB7D-5CE2-4183-85BF-C1DE8DE31A4CQ34285656-20D56551-F7EA-4240-A1B7-3096F51C06EDQ34310912-F378C17B-C2E9-4CD4-8B1B-85331F96B176Q34432692-113BD362-7D9C-4A8A-B6B0-E432FCF5DC74Q34541830-6D236D98-E288-4BFD-B3EB-1A52B521601FQ34594992-B8514A46-AE4B-4B29-ACC3-8D6CFF81A30BQ34687216-BD52A81C-030A-476B-B062-D38CAEF26B7AQ34768412-A333032C-8222-432B-8C28-507B8035F247Q34786691-85A0E2E9-EB1E-4552-9C40-7C2F4447346BQ34795354-187C18DF-95C4-4A58-9002-D79BE4AE68A2Q34823085-72B117C6-A398-445A-9A07-E48C65C8FD76
P2860
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh
1982年學術文章
@zh-hant
name
Cyclophosphamide-facilitated a ...... mor-induced suppressor T cells
@ast
Cyclophosphamide-facilitated a ...... mor-induced suppressor T cells
@en
type
label
Cyclophosphamide-facilitated a ...... mor-induced suppressor T cells
@ast
Cyclophosphamide-facilitated a ...... mor-induced suppressor T cells
@en
prefLabel
Cyclophosphamide-facilitated a ...... mor-induced suppressor T cells
@ast
Cyclophosphamide-facilitated a ...... mor-induced suppressor T cells
@en
P2860
P356
P1476
Cyclophosphamide-facilitated a ...... mor-induced suppressor T cells
@en
P2093
P2860
P304
P356
10.1084/JEM.155.4.1063
P407
P577
1982-04-01T00:00:00Z